PT3707261T - Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos - Google Patents
Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticosInfo
- Publication number
- PT3707261T PT3707261T PT187971627T PT18797162T PT3707261T PT 3707261 T PT3707261 T PT 3707261T PT 187971627 T PT187971627 T PT 187971627T PT 18797162 T PT18797162 T PT 18797162T PT 3707261 T PT3707261 T PT 3707261T
- Authority
- PT
- Portugal
- Prior art keywords
- chemotherapeutics
- protease
- fusion
- carriers
- proteins based
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT201700116184 | 2017-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3707261T true PT3707261T (pt) | 2022-07-13 |
Family
ID=61581399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT187971627T PT3707261T (pt) | 2017-11-06 | 2018-11-05 | Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos |
Country Status (11)
Country | Link |
---|---|
US (1) | US11987604B2 (pt) |
EP (1) | EP3707261B1 (pt) |
JP (1) | JP7297745B2 (pt) |
CN (1) | CN111328346B (pt) |
CA (1) | CA3082076A1 (pt) |
DK (1) | DK3707261T3 (pt) |
EA (1) | EA202090897A1 (pt) |
ES (1) | ES2923152T3 (pt) |
PL (1) | PL3707261T3 (pt) |
PT (1) | PT3707261T (pt) |
WO (1) | WO2019087155A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013024049A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
EP3707261B1 (en) | 2017-11-06 | 2022-05-04 | Thena Biotech S.r.l. | Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers |
WO2021008454A1 (zh) * | 2019-07-12 | 2021-01-21 | 昆山新蕴达生物科技有限公司 | 基于铁蛋白重链亚基的药物载体 |
WO2022179536A1 (zh) * | 2021-02-25 | 2022-09-01 | 昆山新蕴达生物科技有限公司 | 铁蛋白重链亚基突变体及其应用 |
CN115137839A (zh) * | 2021-03-30 | 2022-10-04 | 南京纳么美科技有限公司 | 靶向-共装载亲/疏水药物的铁蛋白笼纳米载体及其应用 |
CN113476588B (zh) * | 2021-07-06 | 2022-11-22 | 武汉大学 | 靶向乳腺癌的多功能纳米颗粒、其制备方法及其应用 |
CN114230671B (zh) * | 2021-11-18 | 2023-12-01 | 中国科学院武汉病毒研究所 | 寨卡病毒重组蛋白疫苗及其制备方法 |
CN116410333A (zh) * | 2021-12-31 | 2023-07-11 | 四川大学 | 一类促凋亡铁蛋白纳米粒和应用 |
CN114292834B (zh) * | 2022-03-09 | 2022-05-31 | 天津辅元生物医药科技有限公司 | 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途 |
CN115181733B (zh) * | 2022-05-26 | 2023-11-21 | 中国农业科学院北京畜牧兽医研究所 | 相对定量分析猪铁蛋白重链fth1的肽段组合物及应用 |
CN114886873B (zh) * | 2022-06-15 | 2023-03-24 | 南京林业大学 | 一种负载sn-38的铁蛋白纳米粒及其制备方法和应用 |
WO2024110757A1 (en) * | 2022-11-24 | 2024-05-30 | King's College London | Control of nanocage self-assembly |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1670931A2 (en) * | 2003-09-05 | 2006-06-21 | GTC Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
KR101631323B1 (ko) | 2007-06-21 | 2016-06-17 | 엑스엘-프로테인 게엠베하 | 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 |
WO2014037373A1 (en) | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
PT3186192T (pt) * | 2014-09-30 | 2018-04-09 | Thena Biotech S R L | Uma proteína de fusão, uma nanopartícula composta por uma pluralidade de monómeros da dita proteína de fusão e utilizações das mesmas |
EP3707261B1 (en) | 2017-11-06 | 2022-05-04 | Thena Biotech S.r.l. | Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers |
-
2018
- 2018-11-05 EP EP18797162.7A patent/EP3707261B1/en active Active
- 2018-11-05 CA CA3082076A patent/CA3082076A1/en active Pending
- 2018-11-05 ES ES18797162T patent/ES2923152T3/es active Active
- 2018-11-05 CN CN201880071815.5A patent/CN111328346B/zh active Active
- 2018-11-05 EA EA202090897A patent/EA202090897A1/ru unknown
- 2018-11-05 WO PCT/IB2018/058655 patent/WO2019087155A1/en unknown
- 2018-11-05 US US16/761,303 patent/US11987604B2/en active Active
- 2018-11-05 JP JP2020524648A patent/JP7297745B2/ja active Active
- 2018-11-05 DK DK18797162.7T patent/DK3707261T3/da active
- 2018-11-05 PL PL18797162.7T patent/PL3707261T3/pl unknown
- 2018-11-05 PT PT187971627T patent/PT3707261T/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CN111328346B (zh) | 2023-06-23 |
JP7297745B2 (ja) | 2023-06-26 |
WO2019087155A1 (en) | 2019-05-09 |
US11987604B2 (en) | 2024-05-21 |
EA202090897A1 (ru) | 2020-08-28 |
DK3707261T3 (da) | 2022-07-11 |
EP3707261A1 (en) | 2020-09-16 |
PL3707261T3 (pl) | 2022-09-12 |
CN111328346A (zh) | 2020-06-23 |
ES2923152T3 (es) | 2022-09-23 |
US20210403515A1 (en) | 2021-12-30 |
EP3707261B1 (en) | 2022-05-04 |
JP2021509104A (ja) | 2021-03-18 |
CA3082076A1 (en) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3707261T3 (pl) | Białka fuzyjne na bazie ludzkiej ferrytyny i peptydów możliwych do cięcia za pomocą proteazy oraz ich zastosowanie jako nośników chemioterapeutycznych | |
AU201810677S (en) | Skin treatment article | |
AU201714140S (en) | Skin treatment article | |
AU201714143S (en) | Skin treatment article | |
AU201810686S (en) | Skin treatment article | |
PL3235830T3 (pl) | Kompleks białkowy interleukiny 15 i jego zastosowanie | |
IL253872A0 (en) | Unnatural semaphorins 3 and their medicinal use | |
AU201810683S (en) | Skin treatment article | |
EP3405222C0 (en) | NEW POLYPEPTIDES AND THEIR MEDICAL USES | |
AU201810689S (en) | Skin treatment article | |
AU201810685S (en) | Skin treatment article | |
AU201714141S (en) | Skin treatment article | |
SG11201909751TA (en) | Human alpha fetoprotein-specific t cell receptors and uses thereof | |
AU201810687S (en) | Skin treatment article | |
PT3684855T (pt) | Material compósito e a sua utilização | |
EP3587440A4 (en) | HUMAN HIGH PROTEIN INFFINITY PD-L1 PEPTIDE AND USES THEREOF | |
SG11202006669RA (en) | Peptides and uses thereof | |
HK1253725A1 (zh) | 新型抗微生物肽及其用途 | |
IL272050A (en) | Synthetic proteins and their therapeutic uses | |
SG11202004529XA (en) | Transformed human cell and use thereof | |
PT3680299T (pt) | Tinta mate e material de pele | |
IL272164B1 (en) | 3-Acyl-benzamides and their use as herbicides | |
ZA201904386B (en) | S-arrestin peptides and therapeutic uses thereof | |
AU201810676S (en) | Skin treatment article | |
HUE062120T2 (hu) | Peptid-származék és alkalmazása |